Floatz logo

rc48-adc

HER2-negative Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciencesantibody_drug_conjugatePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

136 Active assets in the HER2-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capecitabine
Kristina A. Fanucci
Phase 4BB
FULVESTRANT
Olema Pharmaceuticals, Inc.
Phase 4BB
(+)-VINCRISTINE
GI Innovation, Inc.
Phase 4BB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BB
Irinotecan
GI Innovation, Inc.
Phase 4BB

View all 50 →

Same molecule, other indications

rc48-adc is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →